CVS Health Corporation (CVS)
CVS Health Corporation (CVS) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to CVS Health (CVS). This makes it worthwhile to examine what the stock has in store.
CVS Health (CVS) Surges 5.9%: Is This an Indication of Further Gains?
CVS Health (CVS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
US Health Insurance Stocks Rally After $25 Billion Federal Boost To Medicare Payments
Health insurance stocks soared Tuesday morning on the first full day of trading after the U.S. government announced a more than 5% average increase in government reimbursement rates for 2026 Medicare Advantage plans run by private insurers.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
CVS Health's financial chief to step down, Bloomberg News reports
CVS Health Corp Chief Financial Officer Thomas Cowhey intends to step down from his position, Bloomberg News reported on Monday, citing people familiar with the matter.
CVS Health Takes the Lead in 2025 S&P 500 Chart: Is It a Buy Now?
CVS Health's strong track record of stable cash generation aids it amid the broader market sell-offs due to escalating 2025 Trump tariffs.
CVS Health's Trough Years Are Here - Double Digits Return Profile Ahead
CVS has been worst hit by the rising healthcare utilization/ medical costs, as observed in the relatively higher medical benefit ratio in FQ4'24/ FY2024 compared to its peers. Even so, we believe that FY2024 (and maybe FY2025) are likely to be its trough years, as the management offers promising guidance and the consensus raises forward estimates. Despite industry-wide issues, CVS remains well positioned to weather through the near-term uncertainties, thanks to the pricing increases and the stable balance sheet health.
CVS Health: Undervalued, But The Road To Success Is Paved With Uncertainty
I rate CVS Health as a BUY due to its undervaluation and potential for financial growth despite current sector uncertainties. CVS's revenue is growing, but profitability is declining due to retail competition and PBMs shrinking reimbursement rates. CVS's PBM business, Caremark, holds a significant market share, positioning it better than competitors like Walgreens.
Why CVS Health (CVS) is Poised to Beat Earnings Estimates Again
CVS Health (CVS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Live Update: High-Yield Dividends Stocks React to China's Tariff Retaliation
The stock market remains in freefall, today on fears of a full-blown trade war having been ignited, sending the stock market officially into correction turf.
CVS Health (CVS) Rises Yet Lags Behind Market: Some Facts Worth Knowing
In the most recent trading session, CVS Health (CVS) closed at $68.07, indicating a +0.13% shift from the previous trading day.
CVS Health and Deckers Are the S&P 500's Best and Worst for the Quarter. Here's Why.
CVS Health gained 50% over the three-month period while Deckers fell nearly as much.
